Rationale: L-type Ca 2؉ (Ca V 1.2) channels shape the cardiac action potential waveform and are essential for excitation-contraction coupling in heart. A gain-of-function G406R mutation in a cytoplasmic loop of Ca V 1.2 channels causes long QT syndrome 8 (LQT8), a disease also known as Timothy syndrome. However, the mechanisms by which this mutation enhances Ca V 1.2-LQT8 currents and generates lethal arrhythmias are unclear.
L
-type Ca 2ϩ (Ca V 1.2) channels are expressed in the sarcolemma of atrial and ventricular myocytes, where they play a critical role in activating Ca 2ϩ release from the sarcoplasmic reticulum (SR) during excitation-contraction (EC) coupling. The magnitude and time course of the Ca V 1.2 current determine the waveform of the cardiac action potential (AP). 1 Thus, changes in Ca V 1.2 channel function can have profound effects on cardiac EC coupling and excitability. Accordingly, a recent study 2 discovered that a single amino acid substitution (G406R) in Ca V 1.2 is linked to Timothy syndrome. Timothy syndrome is characterized by prolongation of the electrocardiogram (ECG) QT interval and lethal arrhythmias, which is why it is also known as long QT syndrome 8 (LQT8). Interest in the mechanisms of LQT8 has been intense because it is a multisystem disease, with many patients also afflicted by autism. Thus, a single amino acid mutation in Ca V 1.2 causes clinically significant disorders in the cardiac and central nervous systems.
Electrophysiological studies have revealed 2 distinctive features of LQT8 mutant Ca V 1.2 channels (Ca V 1.2-LQT8). First, these channels inactivate at a slower rate than do wild-type (WT) channels. [2] [3] [4] Second, small clusters of Ca V 1.2-LQT8 channels have a higher probability of undergoing coordinated openings and closings ("coupled gating") than do WT channels. 5 Although recent reports suggested that the G406R substitution in Ca V 1.2 creates a new phosphorylation site for the Ca 2ϩ /calmodulin-dependent kinase II (CaMKII), which contributes to an increase in the open probability (P o ) of Ca V 1.2-LQT8 channels, others suggested that phosphorylation by CaMKII is not necessary for their slower rate of inactivation. 4, 6, 7 Thus, the mechanism by which the activity of Ca V 1.2-LQT8 channels is coordinated to generate irregular cardiac rhythm is unclear.
A potential mechanism regulating the activity of Ca V 1.2-LQT8 channels involves the anchoring protein AKAP150.
AKAP150 targets specific protein kinases and phosphatases to regions near Ca V 1.2 channels in ventricular myocytes and neurons. 8, 9 Furthermore, AKAP150 binds to the carboxyl tail of Ca V 1.2 channels via leucine zipper (LZ) motifs in these 2 proteins, 10 facilitating physical interactions between Ca V 1.2 carboxyl tails. AKAP150 increases the probability of long openings and coupled gating events between Ca V 1.2 channels. 5 At present, however, whether the interaction with AKAP150 modulates the abnormal Ca V 1.2-LQT8 channel activity is unknown.
Here, we used a combination of cellular, molecular, imaging, and electrophysiological approaches to investigate this important issue. We discovered that AKAP150 is required for abnormal gating of Ca V 1.2-LQT8 channels. Importantly, our data indicate that ablation of AKAP150 corrects arrhythmogenic Ca V 1.2-LQT8 channel activity in ventricular myocytes.
Methods
An expanded Methods section is available in the Online Supplemental Material at http://circres.ahajournals.org.
Mice were euthanized using a lethal dose of sodium pentobarbital as approved by the University of Washington Institutional Animal Care and Use Committee. Details about the generation of our LQT8 mouse are available in the Online Supplemental Material. Ventricular myocytes were isolated as described previously. 8 Electrophysiological signals were recorded using HEKA EPC10 or Axopatch 200B amplifiers. Images were obtained using a confocal microscope. Data are presented as meanϮSEM. A probability value of less than 0.05 was considered significant. An asterisk was used in the figure to illustrate a significant difference between groups.
Results

Ablation of AKAP150 Protects Against Cardiac Hypertrophy During LQT8
We generated a transgenic mouse that expresses Ca V 1.2-LQT8 channels fused to the tag-red fluorescent protein (tRFP) solely in cardiac myocytes (LQT8; Figure 1A ) and crossed them with AKAP150 null mice (LQT8/AKAP150 Ϫ/Ϫ ). 11 Online Table I summarizes 21 different anatomic and functional features of these mice. We found that the heart-to-body weight ratio of LQT8 hearts was larger than that of WT, AKAP150 Ϫ/Ϫ , and LQT8/AKAP150 Ϫ/Ϫ mice. Indeed, LQT8 myocytes were longer and wider than WT, AKAP150 Ϫ/Ϫ , and LQT8/AKAP150 Ϫ/Ϫ myocytes ( Figure  1B) . Ca V 1.2-LQT8 channels comprised 41%Ϯ5 (nϭ6 mice) and 43%Ϯ4% (nϭ6 mice) of the total sarcolemmal Ca V 1.2 population in LQT8 and LQT8/AKAP150 Ϫ/Ϫ myocytes, respectively. As with Ca V 1.2-WT channels in WT and AKAP150 Ϫ/Ϫ myocytes, Ca V 1.2-LQT8 channels were prominently expressed along the transverse tubules (T-tubules) of LQT8 and LQT8/AKAP150 Ϫ/Ϫ myocytes. However, unlike Ca V 1.2-WT channels, Ca V 1.2-LQT8 channels were also expressed in the intercalated discs and seemed to form multiple clusters in the sarcolemma and near the nuclear envelope of LQT8 and LQT8/AKAP150
Ϫ/Ϫ cells ( Figure 1C ). The number of Ca V 1.2-LQT8 clusters were similar in LQT8 (Online Figure II , 154Ϯ7 clusters/cell, nϭ7) and LQT8/ AKAP150 Ϫ/Ϫ cells (142Ϯ68 clusters/cell, nϭ5; PϾ0.05) (see Online Supplemental material for a description of this analysis). Collectively, these data suggest that Ca V 1.2-LQT8 and CaV1.2-WT channels are differentially expressed in ventricular myocytes, but that AKAP150 does not regulate the expression or distribution of these channels in these myocytes.
Loss of AKAP150 Restores Normal Inactivation of I Ca in LQT8 Myocytes
We recorded macroscopic Ca V 1.2 currents (I Ca ) from WT, AKAP150 Ϫ/Ϫ , LQT8, and LQT8/AKAP150 Ϫ/Ϫ ventricular myocytes. Although the amplitude of I Ca was similar in WT, AKAP150 Ϫ/Ϫ , LQT8, and LQT8/AKAP150 Ϫ/Ϫ ventricular myocytes (PϾ0.05), there were striking differences in the rate of inactivation of these currents (Figure 2A and 2B and  Online Table I ). Indeed, the fraction of I Ca remaining 50 ms (r 50 ) after the onset of depolarization to ϩ10 mV from LQT8 myocytes was larger (nϭ8) than in WT (nϭ9) and AKAP150 Ϫ/Ϫ myocytes (nϭ5; PϽ0.05), suggesting expression of functional Ca V 1.2-LQT8 channels in LQT8 myocytes. Indeed, from these I Ca currents, we determined that Ca V 1.2-LQT8 channels account for Ϸ32% of the total Ca V 1.2 channel population in LQT8 myocytes (see Online Supplemental Material). Interestingly, the r 50 of I Ca in LQT8/ AKAP150 Ϫ/Ϫ (nϭ9) was similar to that of WT and AKAP150 Ϫ/Ϫ . These data suggest that loss of AKAP150 restores normal I Ca inactivation in LQT8 myocytes.
Our I Ca data raise an important question: is AKAP150 required for the expression of functional Ca V 1.2-LQT8 channels? To address this question, we expressed these channels
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A A potential mechanism by which AKAP150 could promote a slow rate of inactivation of Ca V 1.2-LQT8 currents is by acting as an anchor for protein kinase A (PKA). 8, 10 Another possibility is that the effects of AKAP150 on Ca V 1.2-LQT8 channel inactivation depend on CaMKII activity. Application of ht31 (PKA-AKAP interaction inhibitor, 10 mol/L), RpcAMP (PKA inhibitor, 100 mol/L), or KN-93 (CaMKII inhibitor, 5 mol/L) did not change the r 50 of I Ca in LQT8 myocytes (Online Figure I, PϾ0.05 ), which suggests that PKA or CaMKII activity is not responsible for the potentiation of I Ca during LQT8. Furthermore, these data support the view that the necessity of AKAP150 for decreased Ca V 1.2-LQT8 channel inactivation is not dependent on CaMKII activity or its ability to target PKA locally.
AKAP150 Is Required for Increased Ca V 1.2 Channel Activity and Coupled Gating Seen in LQT8 Myocytes
To test the hypothesis that ablation of AKAP150 decreases the P o , open time, and frequency of coupled gating events by Ca V 1.2 channels in LQT8 myocytes, we recorded the in situ activity of Ca V 1.2 channels in WT, LQT8, and LQT8/ AKAP150 Ϫ/Ϫ myocytes using the cell-attached configuration of the patch clamp technique ( Figure 3A and Online Table I Ϫ/Ϫ myocytes (tRFP fluorescence). Below each image, the section of the cell contained within the white rectangles is shown at higher magnification.
nϭ12 cells), and LQT8/AKAP150
Ϫ/Ϫ (0.58Ϯ0.12 pA, nϭ10 cells) myocytes at Ϫ30 mV (PϾ0.05). Consistent with our I Ca data, the activity (ie, NP o where N is the number of channels and P o is the open probability) of Ca V 1.2 channels in LQT8 myocytes (0.11Ϯ0.04) was Ϸ10-fold higher than in WT (0.01Ϯ0.01) and LQT8/AKAP150 Ϫ/Ϫ (0.02Ϯ0.01) myocytes (PϽ0.05; Figure 3B Ϫ/Ϫ myocytes could be fit with a single exponential function with a time constant ( short ) of 0.8 ms and 0.6 ms, and the open time histogram of Ca V 1.2 channels in LQT8 myocytes could be fit with the sum of 2 exponential functions with short of 1.3 ms and long of 9.4 ms, which accounted for 95% and 5% of the channel openings, respectively ( Figure 3B ). The time constants from LQT8 myocytes likely represents a mixed population of WT and LQT8 Ca V 1.2 channels operating in 2 gating modalities in LQT8 myocytes. By contrast, the long Ca V 1.2 channel openings observed in LQT8 myocytes were completely absent in LQT8/AKAP150
Ϫ/Ϫ cells. Collectively, these data suggest that AKAP150 is required for long openings of Ca V 1.2 channels in LQT8 myocytes.
To test the hypothesis that Ca V 1.2-LQT8 channels have a higher probability of coupled gating than do Ca V 1.2-WT channels in ventricular myocytes, we implemented a coupled Markov chain model to determine the coupling coefficient () among Ca V 1.2 channels. 5, 12 The mean coupling coefficient was 0.13Ϯ0.03 for Ca 2ϩ channels in LQT8 myocytes and 0.03Ϯ0.01 for WT and 0.03Ϯ0.01 for LQT8/AKAP Ϫ/Ϫ cells ( Figure 3D ). Indeed, the frequency of coupled gating events ( Ͼ 0.1) was higher in LQT8 (43%Ϯ10%) myocytes than in WT (8%Ϯ4%) and LQT8/AKAP150 Ϫ/Ϫ (10%Ϯ6%) myocytes (PϽ0.05; Figure 3E ).
Loss of AKAP150 Restores Normal [Ca
2؉ ] i , AP Waveform, and Cardiac Rhythm in LQT8 Mice
We recorded AP-evoked [Ca 2ϩ ] i transients in WT, LQT8, AKAP150 Ϫ/Ϫ , and LQT8/AKAP150 Ϫ/Ϫ myocytes ( Figure  4A and Online Table I 8 we examined the effects of the ␤-adrenergic agonist isoproterenol (ISO, 100 nmol/L) on WT, LQT8, AKAP150 Ϫ/Ϫ , and LQT8/AKAP150 Ϫ/Ϫ myocytes ( Figure  4A and Online Table I viding functional confirmation of the loss of AKAP150 in these cells (PϽ0.05). ISO also increased the number of spontaneous Ca 2ϩ release events in Ca V 1.2-LQT8 cells from 40% to 85%, but not in WT, AKAP150 Ϫ/Ϫ , and LQT8/ AKAP150 Ϫ/Ϫ myocytes. We investigated whether restoration of normal inactivation of I Ca in LQT8/AKAP150 Ϫ/Ϫ myocytes translated to changes in AP waveform in these cells. Consistent with our I Ca data, the duration of the AP at 90% repolarization (APD 90 ) was longer in LQT8 (nϭ10) than in WT (nϭ5), AKAP150 Ϫ/Ϫ (nϭ5), and LQT8/AKAP150 Ϫ/Ϫ (nϭ11) myocytes (PϽ0.05; Figure 4B and Online Table I ). In addition, analysis of records with trains of APs revealed that LQT8 myocytes had a higher frequency of early (EADs) and delayed afterdepolarizations (DADs) than did WT, AKAP150
Ϫ/Ϫ , and LQT8/ AKAP150 /Ϫ myocytes ( Figure 4C and Online Table I ). To determine the electrophysiological phenotype of WT, LQT8, AKAP150 Ϫ/Ϫ , and LQT8/AKAP150 Ϫ/Ϫ mice, we implanted telemetric ECG transmitters 13 ( Figure 4D and Online Table I ). Heart rate was similar in WT (nϭ6), LQT8 (nϭ5), AKAP150
Ϫ/Ϫ (nϭ6), and LQT8/AKAP150 Ϫ/Ϫ at rest (nϭ6) or during mild exercise (PϾ0.05). However, consistent with our I Ca and AP data, the QT interval-corrected for heart rate using Bazet's formula (ie, QT c )-of LQT8 mice (116Ϯ1 ms) is longer than that of WT (97Ϯ1 ms), AKAP150
Ϫ/Ϫ (98Ϯ1 ms), and LQT8/AKAP150 Ϫ/Ϫ mice (108Ϯ1 ms; PϽ0.05). During exercise, although multiple premature ventricular depolarizations (PVDs) and episodes of torsades de pointes (TdPs, a hallmark of LQT) were observed in LQT8 mice, none was recorded from WT, AKAP150 Ϫ/Ϫ , and LQT8/AKAP150 Ϫ/Ϫ mice ( Figure 4D and Online Table  I ). Thus, loss of AKAP150 was protective against arrhythmias in mice expressing Ca V 1.2-LQT8.
Discussion
Our findings suggest a new model of Ca V 1.2-LQT8 channel dysfunction during Timothy syndrome ( Figure 4E ). In this model, the anchoring protein AKAP150 and Ca V 1.2-LQT8 form a complex that is necessary for aberrant Ca V 1.2-LQT8 channel gating and arrhythmias. Ca V 1.2-LQT8 channels likely interact with AKAP150 via LZ motifs in the carboxyl tails of both proteins. 10 We propose that AKAP150 functions like an allosteric modulator of Ca V 1.2-LQT8 channels, increasing Ca V 1.2-LQT8 currents by stabilizing the open conformation and increasing the probability of coupled gating between Ca V 1.2-LQT8 channels. This leads to increased Ca 2ϩ influx, AP prolongation, cardiac hypertrophy, and arrhythmias. Coupled gating of Ca V 1.2-LQT8 channels presumably occurs because AKAP150 promotes physical interactions of adjacent channels via their carboxyl tails. 5, 10, 14 Our data provide insights into the cellular mechanisms by which Ca V 1.2-LQT8 channels increase the probability of arrhythmias. We found that expression of Ca V 1. 
Novelty and Significance
What Is Known?
• A single amino acid substitution in Ca V 1.2 L-type Ca 2ϩ channels causes long QT syndrome 8 (LQT8).
• Ca V 1.2-LQT8 channels are characterized by an abnormally slow rate of inactivation and by exhibiting a high frequency of coordinated openings between nearby channels.
• The A-kinase anchoring protein 150 (AKAP150) is a Ca V 1.2 channelassociated scaffolding protein that regulates Ca V 1.2 channel function and excitation-contraction (EC) coupling by targeting adenyl cyclase 5, protein kinase A, and calcineurin near these channels.
What New Information Does This Article Contribute?
• AKAP150 is required for the expression of the LQT8 phenotype in a mouse model of this disease.
• AKAP150 functions like an allosteric modulator of Ca V 1.2-LQT8 channels that increases the opening time and also facilitates coupled gating between these channels in LQT8 cardiac myocytes.
• AKAP150 directly modulates the gating of Ca V 1.2-LQT8 without the aid of kinases.
The mechanism by which the LQT8 mutation alters the function of Ca V 1.2-LQT8 and EC coupling is unclear. Here, we establish that AKAP150 is necessary for the expression of the LQT8 phenotype. We find that AKAP150 functions as an accessory protein to the mutant Ca V 1.2-LQT8 channels, directly modulating the gating of these channels independently of its role in targeting adrenergic signaling. We also find that the coupled gating modality plays an important role in the pathophysiology of LQT8. The increased activity of Ca V 1. where I Ca, WT and I Ca, LQT8 are the currents produced by WT and LQT8 channels, respectively. At +10 mV, I Ca records from WT myocytes suggest that I Ca,WT fully inactivates (i.e., I Ca, WT = 0 pA) at 200 ms. However, our data show that in LQT8 myocytes, I Ca at 200 ms into a voltage step to +10 mV is ~1/3 that of the peak I Ca . For a typical myocyte with a membrane capacitance of 100 pF, and assuming a peak current density of 3 pA/pF (recorded range 2.5-6.0 pA/pF) at +10 mV, the peak I Ca =(100pF)(3 pA/PF)=300 pA. At 200 ms into a voltage step to +10 mV, I Ca =(1/3)(300 pA)=100 pA. Thus, 200 ms into a voltage step to +10mV,
where N is the number of channels, P o is the open probability, R 200 is the fraction current remaining at 200 ms due to Ca 2+ dependent inactivation only, and i Ca is the unitary current of LQT8 channels. Our data suggest that WT and LQT8 channels have similar i Ca . Although i Ca in the presence of physiological 2 mmol/L Ca 2+ at +10 mV is too small to measure, we used published values 1 and fit them with the Goldman, Hodgkin, and Katz (GHK) constant field equation. This gave a predicted i Ca value of 0.05 pA at +10 mV. Assuming a maximum P o value for Ca V 1.2-LQT8 channels of 0.5 and using the published value of 0.75 for R 200 2 , then-N LQT 8 ! 100 pA (0.5* 0.7 * 0.05pA) = 5714
Because at +10 mV, the P o of Ca V 1.2-WT channels is 0.3 3 , we estimated the number of Cav1.2-WT channels at peak I Ca as follows,
Thus, LQT8 channels account for ≈32% of the total number of channels in this exemplar LQT8 myocyte, a value that is in close agreement with our Western blot data (i.e., Ca V 1.2-LQT8 = 41 ± 5% of the total sarcolemmal Ca V 1.2 protein).
PKA or CaMKII do not modulate the rate of inactivation of I Ca in LQT8 myocytes
We tested the hypothesis that AKAP150 modulates Ca V 1.2-LQT8 channel function independent of its ability to target PKA activity to specific regions of the ventricular myocyte. To do this, we recorded I Ca in LQT8 myocytes before and after the application of 100 µM of the PKA inhibitor Rp-cAMP 4 or 10 µM of the PKA-AKAP interaction inhibitor Ht31 5 (Online Figure I) . Consistent with our hypothesis, application of either Rp-cAMP or Ht31 did not change the r 50 of I Ca in LQT8 myocytes, suggesting that PKA is not responsible for the potentiation of I Ca during LQT8. We also test the hypothesis that phosphorylation of Ca V 1.2-LQT8 by CaMKII causes delayed inactivation in these channels. Application of 5 µM of KN-93, a CaMKII inhibitor 6 , did not restore r 50 of I Ca in LQT8 myocytes to WT levels, suggesting CaMKII activity is not required for slow I Ca inactivation in these cells (Online Figure I) . 
Online
Methods and Materials
Generation of LQT8 mice pcDNA3 plasmids encoding WT rabbit Ca V 1.2 Ca 2+ channels (NCBI Reference Sequence: NC_013676.1) were provided by Dr. Diane Lipscombe. We generated the rabbit homolog of the human LQT8 (Timothy syndrome) Ca V 1.2 (G436R, Rabbit; G406R Human) 7 . tRFP was fused to the carboxyl terminal of Ca V 1.2 by fusion PCR cloning (BPS Bioscience). Then, the Ca V 1.2-tRFP was cut out by HindIII and cloned into the vector pBS-αMHC-hGH, a generous gift from Dr. Jeffrey Robbins (University of Cincinnati, Ohio). The construct was linearized by NotI, and the transgene was purified from vector backbone by QIAEX II Gel Extraction Kit (Qiagen). The 13kb transgene was microinjected into pronuclei of fertilized single-cell C57BL/6 × C3H mouse embyos. After injection, the eggs are surgically transferred to the oviducts of time-mated pseudopregnant foster mothers. A combination of PCR and Southern blotting of genomic DNAs identified the founders. The cardiac-specific expression of the transgene was confirmed by RT-PCR and biotinylation Western blot ( Figure 1A-B) .
Isolation of ventricular myocytes
Mice (WT littermates, LQT8, and LQT8/AKAP150 -/-) were euthanized with a lethal dose of sodium pentobarbital administered intraperitoneally as approved by the University of Washington Institutional Animal Care and Use Committee. Ventricular myocytes were isolated using a Langendorff perfusion apparatus as previously described 8, 9 . The isolated ventricular myocytes were kept at room temperature (22-25 o C) in Tyrode's solution with the following constituents (mmol/L): 140 NaCl, 5 KCl, 10 HEPES, 10 glucose, 2 CaCl 2 , and 1 MgCl 2 ; pH 7.4 and used 0.5-6 hours after isolation.
Ca V 1.2 constructs and their expression in mouse embryonic fibroblasts (MEFs)
pcDNA3 plasmids encoding calcium channel accessory subunits (Ca V -β 2a , GenBank accession number: M88751, and Ca V -α 2 δ 1, GenBank accession number: AF286488) were provided by Dr. Diane Lipscombe. Plasmids for the enhanced green fluorescent protein (EGFP) was purchased from Invitrogen. EGFP was fused to the C-terminus of Ca V 1.2 and Ca V 1.2-LQT8, yielding Ca V 1.2-LQT8-EGFP and Ca V 1.2-EGFP. Cultures of MEF cells were maintained in Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum, L-glutamine (2 mmol/L), 1% streptomycin and penicillin solution, 1% Modified Eagle Medium non-essential amino acids, and 100 nM 2-mercaptoethanol. Cells were transiently transfected with the pcDNA3 clones of Ca V 1.2-WT-EGFP or Ca v 1.2-LQT8-EGFP, Ca V -β 2a , and Ca V -α 2 δ 1 using JetPEI (Polyplus). Successfully transfected cells were identified on the basis of EGFP fluorescence.
Coupled Markov chain model
Membrane currents were analyzed using a binary coupled Markov chain model originally described by Chung and Kennedy 10, 11 to simulate and fit independent records of partially coupled channels. The program was written in Matlab ® language. Channel openings were identified using a half-amplitude protocol, with the quantal level for a unitary event set at 0.50 pA for currents. The activity of Ca v 1.2 channels during a patch-membrane recorded I Ca time course was modeled as a first order, discrete Markov chain, and the Markovian transition matrix was estimated from the current and their corresponding channel opening time courses using the built-in Hidden Markov parameter estimation function in Matlab ® . The estimated transition matrix was modeled as a partially coupled Markov chain where a dimensionless parameter (κ) is the coupling coefficient between fully uncoupled and fully coupled cases. In addition to the coupling coefficient (κ), the model has two additional parameters: the channel open-to-open probability (ρ) and the channel closed-to-closed probability (ς), and together they fully describe the contribution from the fully uncoupled case to the transition matrix. For each record, the optimum set of parameters (κ, ρ, ς) for the partially coupled Markov chain model was fitted using a gradient descent algorithm.
The utility of this model is that it is a "lumped" model, where the channels switch between the binary observable states of either "open" or "closed," and therefore, instead of trying to deduce the gating kinetics of multiple channels, which involves many free parameters, our model has only three free parameters, including the coupling coefficient (κ). It does not completely describe the actual kinetics of the channel and consequently the transition probabilities obtained from this lumped model are not interpreted as rate constants.
Electrophysiology
All electrophysiological recordings were performed while cells were superfused with saline solutions at room temperature (≈ 22 ˚C). For whole-cell L-type Ca 2+ currents (I Ca ), membrane potential was controlled via the patch-clamp technique using an EPC10 (HEKA) or an Axopatch 200B amplifier (Molecular Devices). Data were acquired at 10 kHz and low-pass filtered at 5 kHz. Ventricular myocytes and MEFs were continuously superfused with Tyrode's solution. Once whole-cell configuration has been successfully established in myocytes, a solution with the following constituents (mmol/L) was exchanged: 140 NMDG, 5 CsCl 2 , 2 CaCl 2 , 1 MgCl 2 , 10 glucose, 10 HEPES, adjusted to pH 7.4 with HCl, and 50 µM of tetracaine was added to block SR Ca 2+ induced Ca 2+ release. For MEFs experiments, this solution was exchanged for a solution containing a similar composition except that CaCl 2 was 20 mmol/L, NMDG concentration was 120 nM, and no tetracaine was added. Pipettes for whole-cell patch-clamp were pulled using a Flaming-Brown type puller (Sutter Instruments) with nominal resistance of 1-2 MΩ and filled with a solution composed of (mmol/L): 87 Cs-aspartate, 20 CsCl, 1 MgCl 2 , 5 MgATP, 10 EGTA, 10 HEPES, and 4.7 CaCl 2 , adjusted to pH 7.2 with CsOH. The free [Ca 2+ ] was 150 nM, as calculated using the MaxChelator program 12 . I Ca was evoked from both myocytes and MEFs by 200 ms long depolarization pulses from -80 mV to -40 to +50 mV. For myocytes, an additional 100 ms long voltage step to -40 mV immediately preceded the depolarization pulses as to inactivate Ca 2+ conductance through voltage-gated Na + channels. For experiments involving treatments with the chemical inhibitors Rp-cAMP, Ht31, and KN-93, the inhibitors were dissolved in the appropriate external solution for whole-cell I Ca recordings to the appropriate concentration (100 µM for Rp-cAMP, 10 µM Ht31, and 5 µM for KN-93). We recorded post-treatment I Ca 10 minutes after starting superfusion with the inhibitor solution.
For action potential (AP) recordings in ventricular myocytes, we used the whole-cell current clamp mode of the Axopatch 200B amplifier. Cells were continuously superfused with Tyrode's solution. Pipettes for AP recordings had nominal resistance of 1-2 MΩ and filled with a solution composed of (mmol/L): 30 KCl, 110 K-aspartate, 10 HEPES, 10 NaCl, 5 MgATP, adjusted to pH 7.2 with KOH. APs were excited by 5 ms long current injections of 7 nA occurring every 1 s. This relatively slow stimulation rate and low solution temperature (≈ 22 ˚C) likely prolonged the action potential of ventricular myocytes. Membrane voltage records were sampled at 10 kHz and low-pass filtered at 2 kHz. Early afterdepolarizations (EADs) were visually identified as spontaneous depolarizations in membrane voltage during phases II and III of the cardiac AP, while delayed afterdepolarizations (DADs) were visually identified as spontaneous depolarizations in membrane voltage during phase IV of the cardiac AP
We also recorded L-type Ca 2+ channel currents from cell-attached patches in ventricular myocytes. Data were acquired using an Axopatch 200B amplifier at 10 kHz and low-pass filtered at 2 kHz. The patch pipettes were pulled using a Flaming-Brown type puller and heat polished using a microforge (Narishige) with a nominal resistance of 2-3 MΩ. The pipette solution contained (mmol/L): 20 CaCl 2 (charge carrier), 130 TEA, and 10 -3 tetrodotoxin (TTX), adjusted to pH = 7.2 with HCl. Voltage gated Na + channels were blocked with TTX, while voltage gated K + channels were blocked with TEA. The L-type Ca 2+ channel agonist BayK-8644 (500 nM) was included in the pipette solution to increase the mean open time and P o of these channels. Currents were recorded while cells were exposed to a solution containing (mmol/L): 145 KCl, 10 HEPES, and 10 NaCl (pH = 7.4). L-type Ca 2+ channel currents were evoked by a 1 s step depolarization to -30 mV from the holding potential of -80 mV. Membrane currents were analyzed using pCLAMP 10 (Molecular Devices). All experiments were performed at room temperature (22-25 o C).
Confocal imaging of Ca 2+ signals
Ventricular myocytes were loaded with the membrane-permeable acetoxymethyl-ester form of Fluo-4 (Fluo-4 AM, Invitrogen) for measurement of [Ca 2+ ] i as previously described 13 . Cells were placed in a perfusion chamber and incubated with normal Tyrode at 22 -25 °C. Field stimulation was performed with two platinum wires (0.5 cm separation) placed at the bottom of the perfusion chamber. An IonOptix Myopacer (IonOptix Corp) stimulator was used to deliver square voltage pulses (4 ms duration) with amplitude of 35 volts at a frequency of 1 Hz. We imaged temporal fluorescence fluctuations caused by [Ca 2+ ] transients using the line-scan mode (2 ms/line) of our Olympus Fluo View 1000 confocal microscope with an Olympus APON (60X, NA = 1.49) oil-immersion lens. Fluo-4 was excited with a 473 nm solid-state laser. Line-scan images were analyzed using ImageJ. Background subtracted fluorescence signals were normalized by dividing fluorescence at each point (F) with the baseline fluorescence (F 0 ). Spontaneous Ca 2+ release (SCR) events were identified manually as increases in fluorescence that were not elicited by stimulation.
Analysis of the spatial distribution of Ca V 1.2-WT and tRFP-tagged Ca V 1.
2-LQT8 channels
We used immunofluorescence approaches to determine the spatial distribution of Ca V 1.2-WT in WT and AKAP150 -/-myocytes. To do this, myocytes were plated on BD Cell-Tak coated cover slips. Cells were allowed to attach for 4 hrs. Cells were then fixed in a solution containing 2% paraformaldehyde, 75 mM Lysine and 10 mM sodium periodate in phosphate buffer 14 . Cells were washed three times in PBS, and permeabilized with 0.075% Triton X-100/PBS and incubated for 30 min. in blocking buffer containing 2% donkey serum, 20% goat serum, and 1% bovine serum albumin in pearmeabilization solution. Specific L-type Ca V 1.2 channel α-1C subunit (Sigma) antibody was used for immunolabeling of L-type Ca V 1.2 channels. Cells were extensively washed in PBS and incubated for 2 hours with donkey anti-rabbit Alexa Fluor 488-conjugated (5 mg/ml) antibody (Molecular Probes). Cells were visualized using an Olympus Fluo View 1000 confocal laser-scanning microscope equipped with an UPLSAPO 60X water lens (NA = 1.2) and a zoom of 1.9 (pixel size = 0.19 µm).
The same confocal microscope was used to image tRFP-tagged CaV1.2-LQT8 in living, freshly dissociated LQT8 and LQT8/AKAP150 -/-myocytes. tRFP was excited with a 559 nm laser. To quantify the number of tRFP-tagged Ca v 1.2-LQT8 clusters in ventricular myocytes, maximum intensity projections were generated from Z-stacks. Clusters were counted and measured using ImageJ software (NIH). In brief, projected images were loaded into ImageJ. A threshold range that enabled segmentation of clusters from the background was set and the image was 
ECG Telemetry
Ambulatory telemetry recordings were performed in WT littermate, LQT8, AKAP150 -/-, and LQT8/AKAP150 -/-mice. Radiotelemetry ECG monitors (DSI) were implanted intraperiotoneally, with the electrode leads sutured in place subcutaneously over the chest wall and assuming a lead II configuration. The mice were under isoflurane anesthesia during surgery, and they were given buprenorphine for analgesia for 24 hours post-surgery. A week after the surgery the mice were acclimatized to the treadmill exercise regimen. The exercise treadmill (Columbus Instruments) was started at 5 m/min and the shock grid turned on, and the speed was increased by 1 m/min every minute. The mice were exercised for 15 min per session or until they reached exhaustion, which was defined as greater than 5 s spent resting on the shock grid, at which time the shock grid was turned off. After acclimatization, the mice were exercised according to the regimen, during which their ECGs were recorded. The ECG records were analyzed using the ECG Analysis software (DSI), which automatically detected the QT intervals and arrhythmic events.
Western blots
For these experiments, we used acutely dissociated ventricular myocytes from WT littermates, LQT8, AKAP150 -/-, and LQT8/AKAP150 -/-mice. Western blots were performed as recently described 15 . Briefly, myocytes were washed 3 times with ice-cold PBS and subsequently incubated with PBS containing 1.0 mg/ml EZ-Link Sulfo-NHS-LC-LC-biotin (Thermo Scientific) for 60 min at 4°C. After labeling, the cells were washed 3 times in ice-cold PBS containing 100 mmol/L glycine to quench and remove excess biotin reagent and by-products. Biotinylated myocytes were homogenized in RIPA buffer and cellular debris removed by centrifugation. Total protein was then determined by BCA analysis. 480 µg proteins were mixed with 120µl NeutrAvidin agarose resin (Thermo Scientific) and incubated overnight for avidin pull-down of biotinylated surface proteins. Following pull down, the supernatant comprised the nonbiotinylated (cytosolic) protein fraction, while surface proteins remained bound to the avidin beads. Proteins were eluted from beads by boiling in SDS-PAGE sample buffer and analyzed by Western blotting using standard techniques. We also performed Western blotting on crude cell homogenates, proteins pulled down by avidin, and the leftover supernatant against GAPDH, a cytosolic protein, as quality control to ensure the specificity of the biotinylation reaction against membrane proteins (Online Figure III) . Anti-Ca V 1.2 antibody was purchased from Alomone Labs (Cat# ACC-003). Anti-GAPDH antibody was purchased from Sigma-Aldrich (Cat# G8795).
Online Figure III:
Avidin pull-down of biotinylated protein is specific for sarcolemmal proteins. A Western blot showing GAPDH from crude cell homogenate (crude), proteins pulled down by avidin (pull-down), and the remaining supernatant from WT, LQT8, and LQT8/AKAP150 -/-ventricular myocytes. GAPDH, a cytosolic protein, is absent from the avidin bound proteins.
Statistics
Data are presented as mean ± SEM. Two-sample comparisons were made using a student's Ttest. A p value of less than 0.05 was considered significant. The asterisk (*) symbol is used in the figures to illustrate a significant difference between groups (p<0.05).
Supplemental references
